Hurthle cell neoplasm of the thyroid gland
- PMID: 18269475
- DOI: 10.1111/j.1445-2197.2007.04389.x
Hurthle cell neoplasm of the thyroid gland
Abstract
Background: A clinicopathological analysis and long-term follow up of 32 patients with Hurthle cell neoplasm (HCN) was undertaken to contrast the clinical and histological features between benign versus malignant HCN of thyroid and to examine the effect of treatment on the outcome.
Methods: This is a retrospective study of 32 patients with HCN who were identified out of an archival clinical/pathological/imaging database of 3752 thyroid cancer patients seen between 1976 and June 2006. All patients underwent thyroid surgery. Data for the non-surgical treatment along with follow up were also analysed.
Results: Seventeen patients were classified as malignant HCN (MHCN) and 15 as benign HCN (BHCN). Among the MHCN, there were 11 women and 6 men, whereas among BHCN there were 14 women and 1 man. Three patients designated MHCN presented with metastases, one with pulmonary metastases and two others with skeletal metastases who developed lung metastases 9-19 months later. The mean tumour size was 4.43 +/- 0.66 cm for MHCN, and 2.57 +/- 0.32 cm for BHCN (P = 0.03). Multicentric tumour foci were evident in five cases (29%) of MHCN but none among the BHCN (P = 0.03). At neck exploration cervical lymph node dissection was carried out in nine MHCN patients with findings of tumour metastases in 33%. Postoperatively, three MHCN patients had no thyroid remnant on ultrasound and computed tomography of neck and undetectable serum thyroglobulin; these were considered to be in remission. Fourteen other MHCN patients with postoperative thyroid remnant and/or distant metastases received 131I treatment. Eight of these patients had negative whole-body scans after 131I treatment and undetectable thyroglobulin. Accordingly, 11 MHCN patients (64.7%) showed evidence of remission and 6 patients did not respond to 131I treatment. After a mean follow up of 35 months, all BHCN patients are alive with no evidence of disease. Of the MHCN, 11 (64.7%) were in remission and 35% had evidence of persistence/recurrence. One patient who had recurrence is dead. A lack of effectiveness of 131I therapy in two patients with distant metastases is an important finding.
Conclusion: Features of MHCN consisted of a large tumour size, unequivocal capsular and vascular invasion, multicentric tumour foci, metastatic lymph node deposits in one-third of patients and presence of distant metastasis in a few. Findings of dominant Hurthle cell cytology in a fine-needle aspiration biopsy from a thyroid nodule should prompt surgical resection of the lesion to assess malignancy.
Comment in
-
Hurthle cell neoplasm of the thyroid gland.ANZ J Surg. 2008 Mar;78(3):115. doi: 10.1111/j.1445-2197.2007.04381.x. ANZ J Surg. 2008. PMID: 18269467 No abstract available.
Similar articles
-
Hürthle cell carcinoma: a clinicopathological study of thirteen cases.Nucl Med Commun. 2006 Apr;27(4):377-9. doi: 10.1097/01.mnm.0000202862.74917.0c. Nucl Med Commun. 2006. PMID: 16531925
-
Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?Diagn Cytopathol. 2004 Nov;31(5):307-12. doi: 10.1002/dc.20132. Diagn Cytopathol. 2004. PMID: 15468114
-
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?Diagn Cytopathol. 2006 May;34(5):330-4. doi: 10.1002/dc.20440. Diagn Cytopathol. 2006. PMID: 16604553
-
[Hürthle cell tumor of the thyroid gland. Analysis of a series of 33 cases].J Chir (Paris). 1989 Nov;126(11):619-24. J Chir (Paris). 1989. PMID: 2685000 Review. French.
-
[Hürthle-cell thyroid neoplasms: a clinical enigma].Ann Ital Chir. 1999 Jul-Aug;70(4):503-8; discussion 508-9. Ann Ital Chir. 1999. PMID: 10573612 Review. Italian.
Cited by
-
Synchronous occurrence of Hurthle cell carcinoma with Hodgkin's lymphoma; the first reported case with literature review.Ann Med Surg (Lond). 2021 Aug 24;69:102750. doi: 10.1016/j.amsu.2021.102750. eCollection 2021 Sep. Ann Med Surg (Lond). 2021. PMID: 34484724 Free PMC article.
-
Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.Adv Ther. 2021 Oct;38(10):5144-5164. doi: 10.1007/s12325-021-01876-7. Epub 2021 Aug 22. Adv Ther. 2021. PMID: 34423400
-
Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma).PeerJ. 2019 Aug 27;7:e7458. doi: 10.7717/peerj.7458. eCollection 2019. PeerJ. 2019. PMID: 31523497 Free PMC article.
-
The significance of hurthle cells in thyroid disease.Oncologist. 2011;16(10):1380-7. doi: 10.1634/theoncologist.2010-0253. Epub 2011 Sep 30. Oncologist. 2011. PMID: 21964000 Free PMC article. Review.
-
Propensity score matching analysis of the prognosis for the rare oxyphilic subtype of thyroid cancer (Hurthle cell carcinoma).Oncotarget. 2017 Sep 8;8(60):101362-101371. doi: 10.18632/oncotarget.20732. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254170 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical